Papillomavirus prophylactic vaccines: established successes, new approaches.

PubWeight™: 1.00‹?› | Rank: Top 15%

🔗 View Article (PMC 2812340)

Published in J Virol on November 11, 2009

Authors

M Saveria Campo1, Richard B S Roden

Author Affiliations

1: Division of Pathological Sciences, Institute of Comparative Medicine, Garscube Campus, University of Glasgow, Glasgow G61 1QH, United Kingdom. s.campo@vet.gla.ac.uk

Articles citing this

Antiviral immune responses in the genital tract: clues for vaccines. Nat Rev Immunol (2010) 1.45

A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One (2011) 1.28

Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. J Clin Med (2015) 0.98

Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res (2014) 0.96

Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96

Optimization of multimeric human papillomavirus L2 vaccines. PLoS One (2013) 0.95

Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 0.94

Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16. Virology (2011) 0.82

Evidence of association of human papillomavirus with prognosis worsening in glioblastoma multiforme. Neuro Oncol (2013) 0.80

Development of an IP-Free Biotechnology Platform for Constitutive Production of HPV16 L1 Capsid Protein Using the Pichia pastoris PGK1 Promoter. Biomed Res Int (2015) 0.78

Targeting human papillomavirus genome replication for antiviral drug discovery. Antivir Ther (2013) 0.78

Tracking vaginal, anal and oral infection in a mouse papillomavirus infection model. J Gen Virol (2015) 0.77

Long-peptide therapeutic vaccination against CRPV-induced papillomas in HLA-A2.1 transgenic rabbits. Trials Vaccinol (2014) 0.76

A multimeric L2 vaccine for prevention of animal papillomavirus infections. Virology (2011) 0.76

Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines (2016) 0.75

Intranasal immunization of pigs with porcine reproductive and respiratory syndrome virus-like particles plus 2', 3'-cGAMP VacciGrade™ adjuvant exacerbates viremia after virus challenge. Virol J (2017) 0.75

Vaccine generated immunity targets an HPV16 E7 HLA-A2.1-restricted CD8(+) T cell epitope relocated to an early gene or a late gene of the cottontail rabbit papillomavirus (CRPV) genome in HLA-A2.1 transgenic rabbits. Vaccine (2010) 0.75

Articles cited by this

Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46

Classification of papillomaviruses. Virology (2004) 14.16

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72

Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 5.12

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14

Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell (2000) 3.44

The papillomavirus life cycle. J Clin Virol (2005) 3.41

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology (1991) 3.28

Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83

Comparative analysis of the human type 1a and bovine type 1 papillomavirus genomes. J Virol (1983) 2.69

Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology (1992) 2.53

An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine (2008) 2.48

Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J Gen Virol (1993) 2.42

Arrangement of L2 within the papillomavirus capsid. J Virol (2008) 2.37

Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol (2008) 2.37

A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36

Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol (1990) 2.34

The human papillomavirus E7 oncoprotein. Virology (2008) 2.32

Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology (2005) 2.31

Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology (2000) 2.25

The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology (1991) 2.24

How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23

Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol (2008) 2.22

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology (1996) 2.08

Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol (2007) 2.05

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A (2008) 2.00

Animal models of papillomavirus pathogenesis. Virus Res (2002) 1.98

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95

Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem (2007) 1.77

Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J Virol (2008) 1.73

Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. Virology (1991) 1.70

Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol (1994) 1.70

Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol (2007) 1.70

Papillomavirus E6 proteins. Virology (2008) 1.70

Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J Virol (2006) 1.67

Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol (1996) 1.66

Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions. Virology (1997) 1.66

Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol (2001) 1.55

Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol (1998) 1.49

Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol (2002) 1.48

Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology (1995) 1.48

G2/M cell cycle arrest in the life cycle of viruses. Virology (2007) 1.39

Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene (2007) 1.37

Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J Gen Virol (1996) 1.32

Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol (1993) 1.26

Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res (2006) 1.26

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2006) 1.25

Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol (2007) 1.23

Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution. J Mol Biol (1998) 1.23

A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease. Virology (1997) 1.22

E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer (2006) 1.18

Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extract and transformed cells in prophylactic vaccination. Vet Rec (1990) 1.15

Virus-induced papillomas of the alimentary tract of cattle. Int J Cancer (1978) 1.11

Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types. Vet Rec (1990) 1.11

Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer (2006) 1.11

The bovine papillomavirus E5 protein and the PDGF beta receptor: it takes two to tango. Virology (2008) 1.07

Vaccination against papillomavirus in cattle. Clin Dermatol (1997) 1.06

Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus E1, E2, E6, and E7 genes. J Virol (1999) 1.06

Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin. Vaccine (2009) 1.05

Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine (2008) 1.05

Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J Virol (2003) 1.04

Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol (2004) 0.99

Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine (2001) 0.99

Down-regulation of MHC class I is a property common to papillomavirus E5 proteins. Virus Res (2006) 0.98

Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes. Virology (2009) 0.98

Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev (2008) 0.96

How much will it hurt? HPV vaccine side effects and influence on completion of the three-dose regimen. Vaccine (2009) 0.96

The human papillomavirus type 16 E7 protein binds human interferon regulatory factor-9 via a novel PEST domain required for transformation. J Interferon Cytokine Res (2006) 0.91

Papillomavirus and disease in humans and animals. Vet Comp Oncol (2003) 0.91

Loss of epidermal Langerhans cells occurs in human papillomavirus alpha, gamma, and mu but not beta genus infections. J Invest Dermatol (2009) 0.89

Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors. Vaccine (2009) 0.85

Potential strategies utilised by papillomavirus to evade host immunity. Immunol Rev (1999) 0.85

Phenotypical characterization of lymphocytes infiltrating regressing papillomas. J Virol (1996) 0.85

Linear B-cell epitopes in the N-terminus of L2 of bovine papillomavirus type 4. Res Vet Sci (1997) 0.81

Identification of an arginine-rich motif in human papillomavirus type 1 E1;E4 protein necessary for E4-mediated inhibition of cellular DNA synthesis in vitro and in cells. J Virol (2008) 0.81

Human papillomavirus research: do we still need animal models? Int J Cancer (2009) 0.80

Immunity to bovine cutaneous papillomatosis produced by vaccine homologous to the challenge agent. J Am Vet Med Assoc (1959) 0.76

Articles by these authors

CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res (2006) 2.92

A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36

Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology (2005) 2.31

Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol (2008) 2.22

Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A (2008) 2.00

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95

Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol (2007) 1.70

Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68

Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J Virol (2005) 1.61

Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol (2014) 1.46

Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res (2006) 1.41

Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res (2008) 1.33

Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res (2006) 1.28

Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol (2004) 1.27

Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem (2003) 1.27

Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27

Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res (2006) 1.26

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2006) 1.25

Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J Virol (2009) 1.18

B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol (2005) 1.16

Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res (2009) 1.14

Papillomavirus infection requires gamma secretase. J Virol (2010) 1.12

Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther (2005) 1.10

Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One (2012) 1.08

L2, the minor capsid protein of papillomavirus. Virology (2013) 1.07

The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA binding. J Virol (2004) 1.06

Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. Cancer Res (2006) 1.06

Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine (2008) 1.05

Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine (2010) 1.05

Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02

Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol (2005) 1.00

Photonic approach to the selective inactivation of viruses with a near-infrared subpicosecond fiber laser. J Biomed Opt (2010) 0.99

p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol (2009) 0.99

Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol (2011) 0.97

Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility. Am J Pathol (2007) 0.96

Personalized chemotherapy profiling using cancer cell lines from selectable mice. Clin Cancer Res (2013) 0.96

Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics. Proteomics (2011) 0.96

Optimization of multimeric human papillomavirus L2 vaccines. PLoS One (2013) 0.95

Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res (2013) 0.92

Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am J Pathol (2008) 0.92

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol (2013) 0.92

Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol (2010) 0.92

Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines (2013) 0.90

Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species. Virology (2012) 0.89

α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells. J Med Chem (2010) 0.88

Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells. PLoS One (2011) 0.87

The future of vaccines for cervical cancer. Gynecol Oncol (2008) 0.87

Human papillomavirus type-16 virus-like particles activate complementary defense responses in key dendritic cell subpopulations. J Immunol (2004) 0.85

Immunohistochemical detection of human papillomavirus capsid proteins L1 and L2 in squamous intraepithelial lesions: potential utility in diagnosis and management. Mod Pathol (2012) 0.85

Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr Opin Investig Drugs (2004) 0.85

The high risk HPV16 L2 minor capsid protein has multiple transport signals that mediate its nucleocytoplasmic traffic. Virology (2011) 0.85

Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation. PLoS One (2013) 0.84

Capsomer vaccines protect mice from vaginal challenge with human papillomavirus. PLoS One (2011) 0.83

HPV pseudovirions as DNA delivery vehicles. Ther Deliv (2011) 0.83

A multimeric L2 vaccine for prevention of animal papillomavirus infections. Virology (2011) 0.76

Vaccines against human papillomavirus. Front Biosci (2007) 0.76

GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility. Am J Surg Pathol (2015) 0.75